
Regina Hartfield is the new CEO and president of the Sickle Cell Association of America. Listen to our interview with her to find out what's in store for 2022.

Regina Hartfield is the new CEO and president of the Sickle Cell Association of America. Listen to our interview with her to find out what's in store for 2022.

Upadacitinib is now indicated for children 12 years and older, and can be used as a monotherapy or with topical corticosteroids.

Baez-Sosa explains why further investigation of alloimmunization in patients with sickle cell disease is crucial.

Exciting new therapies for sickle cell disease are on the horizon. We explored some of the most promising investigational therapies in recognition of National Blood Donor Month.

Beach shares about Haywood's life, research, and impact on the sickle cell disease community after working alongside him at Johns Hopkins School of Medicine.

Achebe explains the promising results of the open label extension to the HOPE trial for patients with sickle cell disease.

Sexual activity was involved in 0.2% of all SCDs, with sudden arrhythmic death syndrome and cardiomyopathies predominant underlying causes.

Exposure to long-term prescription opioid therapy was linked to a 3.2-fold higher risk of HCV seroconversion compared to individuals who were prescription opioid-naïve or acute.

Trials of CBP-201 for asthma and chronic rhinosinusitis with nasal polyps are ongoing, and early data from the atopic dermatitis trial were promising.

The study suggests a platform that can be integrated into surgical ophthalmic microscopes can provide real-time audiovisual feedback to the surgeon during phacoemulsification cataract surgery.

Brexipiprazole has been previously approved for adults with schizophrenia and adults with major depressive disorder.

The discriminative accuracy of the 3 instruments were evaluated in low- and middle-income settings in Nepal, Peru, and Uganda, with further research needed to determine whether implementation is associated with improved clinical outcomes.

Dr. Talbot speaks to the variety of different strains of influenza, and how research into different flu vaccines could be informed by advancements made in the management of shingles and COVID-19.

Adverse event rates did not significantly differ between patients treated with both DAV132 and Fluoroquinolone and patients treated only with fluoroquinolone.


A new survey shows physicians are voting more frequently. A study author explains what that may mean for the civic involvement of doctors.

More research is needed on how the various FODMAP diets impact the gut microbiota and IBD management.

Factors associated with a physical decline include greater BMI, less educational attainment, current smoking, osteoarthritis, clinically significant depressive symptoms, and cardiovascular disease.

Investigators concluded that long-term data are needed regarding surgery, but confirmed it to be more efficacious than medical therapy alone.

Between 20-30% of patients with schizophrenia do not respond to the first-line antipsychotic treatment.

Abbott's device is designed to create highly detailed 3-dimensional maps of the heart to help physicians identify and treat abnormal rhythms.

Deaths attributed to pneumonia, influenza, and COVID-19 were above the epidemic threshold, per the latest CDC report.

Investigators examine the impact that 1 or 2 doses of dexamethasone has on morphine consumption and postoperative pain in patients undergoing a total knee arthroplasty.

A study found psychotropic medication use was associated with a higher risk of 1 year all-cause mortality, regardless of self-reported symptoms of anxiety.

The skin disease was also linked to higher levels of glucosyl cholesterol which was strongly associated with disease severity.

The results suggested that the microbial changes were secondary in the pathogenesis of the skin disease.

A recent study showed anticoagulant therapy for 6 weeks compared to 3 months met noninferiority criteria, based on a combination of recurrent VTE risk and bleeding risk.

The Cochlear Nucleus Implant was previously approved for patients with moderate to profound bilateral sensorineural hearing loss.

There remains a paucity of data for very early onset pediatric IBD in the majority of countries.

Dr. Silverberg speaks of the recent FDA approval of the biologic for patients with moderate-to-severe atopic dermatitis.